作者: Laura Martínez-Aguilar , Cristina Pérez-Ramírez , María del Mar Maldonado-Montoro , María Isabel Carrasco-Campos , Cristina Membrive-Jiménez
DOI: 10.1016/J.MRREV.2020.108322
关键词:
摘要: Abstract Treatment with interferon beta (IFNβ) is one of the first-line treatments for multiple sclerosis. In clinical practice, however, many patients present suboptimal response to IFNβ, …